FDA Grants Breakthrough Designation for Datar Cancer Genetics Early-Stage Prostate Cancer Detection Blood Test
TriNetra-Prostate™ is a Circulating Tumor Cell detection blood test to identify early-stage Prostate Cancer with high accuracy in men of age 55-69 years
BOSTON, Feb. 14, 2022 /PRNewswire/ -- Datar Cancer Genetics Inc today announced that the US Food and Drug Administration (FDA) has granted 'Breakthrough Device Designation' for its 'TriNetra-Prostate™' blood test to detect early-stage prostate cancer. This is the second test from the Company that has received the Breakthrough Device Designation from the US FDA. Last year, the Company's early-stage breast cancer detection test became the first such test to receive the Breakthrough Device Designation.
In the United States, prostate cancer is the third most common type of cancer; each year, more than 200,000 men are detected with prostate cancer and is associated with more than 32,000 deaths. The test can identify individuals who are more likely to harbour cancer in the prostate and aids clinical decision making such as the need to undergo a biopsy for confirmatory diagnosis.
Studies have shown that TriNetra-Prostate™ can detect early-stage cancer with high accuracy (>99%) without any false positives. TriNetra-Prostate™ requires 5 ml blood and is indicated for males of age 55-69 years with serum PSA of 3 ng/mL or higher. TriNetra-Prostate™ is based upon the detection of prostate adenocarcinoma specific Circulating Tumor Cells (CTCs) in the blood.
"The breakthrough device designation is a recognition of the potential benefits of TriNetra-Prostate™ in the clinical setting. The test can help reduce the number of biopsies among individuals with benign conditions of the prostate and it can also improve detection rates among those who do have prostate cancer. With our proprietary CTC-enrichment and detection technology, there is virtually no risk of false positives among individuals who do not have prostate cancer," said Dr Vineet Datta, Executive Director of the Company. The test has previously received CE certification and is already available in Europe as 'Trublood-Prostate'.
The Breakthrough Device Designation is granted by the FDA for devices that demonstrate a potential for more effective diagnosis of life-threatening diseases such as cancer. The Breakthrough Devices Program intends to provide patients and healthcare providers with timely access to medical devices granted such designation by prioritized review to expedite development and assessment.
About Datar Cancer Genetics
Datar Cancer Genetics is a global oncology research and applications company specializing in non-invasive technologies for improved detection, treatment, and management of cancer. The Company's state-of-the-art facility is NABL, ISO, CAP, CLIA accredited and serves cancer patients and suspected cases globally. The Company is pursuing large clinical studies in the United States to cover multiple cancers where there is a potential of cure with early detection and proposes to have multiple test centers in the United States and globally.
Contact: Dr Vineet Datta
[email protected]
Website: trubloodprostate.com
SOURCE Datar Cancer Genetics
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article